[go: up one dir, main page]

WO2009002790A3 - Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye - Google Patents

Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye Download PDF

Info

Publication number
WO2009002790A3
WO2009002790A3 PCT/US2008/067419 US2008067419W WO2009002790A3 WO 2009002790 A3 WO2009002790 A3 WO 2009002790A3 US 2008067419 W US2008067419 W US 2008067419W WO 2009002790 A3 WO2009002790 A3 WO 2009002790A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
ameliorating
alleviating
treating
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/067419
Other languages
French (fr)
Other versions
WO2009002790A2 (en
Inventor
Jinzhong Zhang
Keith Wayne Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of WO2009002790A2 publication Critical patent/WO2009002790A2/en
Publication of WO2009002790A3 publication Critical patent/WO2009002790A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an ophthalmologic disorder that has an etiology in inflammation comprise an antagonist to a toll-like receptor ('TLR'), a coreceptors thereof, or a combination thereof. The compositions can also include another anti¬ inflammatory medicament.
PCT/US2008/067419 2007-06-26 2008-06-19 Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye Ceased WO2009002790A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94626107P 2007-06-26 2007-06-26
US60/946,261 2007-06-26

Publications (2)

Publication Number Publication Date
WO2009002790A2 WO2009002790A2 (en) 2008-12-31
WO2009002790A3 true WO2009002790A3 (en) 2009-03-19

Family

ID=39887712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067419 Ceased WO2009002790A2 (en) 2007-06-26 2008-06-19 Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye

Country Status (1)

Country Link
WO (1) WO2009002790A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
WO2017085740A1 (en) * 2015-11-17 2017-05-26 Council Of Scientific & Industrial Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
HUE061248T2 (en) * 2018-03-27 2023-06-28 Neuropore Therapies Inc Compounds as modulators of tlr2 signaling
MX2021011596A (en) 2019-03-26 2021-10-13 Neuropore Therapies Inc Compounds and compositions as modulators of tlr signaling.
CN116710135A (en) 2020-10-07 2023-09-05 6线生物技术公司 Methods and reagents for treating ocular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862916A1 (en) * 1995-11-20 1998-09-09 Kiyoshi Kita External preparation containing vitamin d or vitamin k
EP0992242A1 (en) * 1997-06-10 2000-04-12 New Vision Co., Ltd. Vitamin d-containing preventives and/or remedies for conjunctival/corneal xerosis
US20050265998A1 (en) * 2003-12-10 2005-12-01 Greg Elson Neutralizing antibodies and methods of use thereof
WO2006121871A2 (en) * 2005-05-06 2006-11-16 The Scripps Research Institute Compositions and methods for modulating cells via cd14 and toll-like receptor 4 signaling pathway

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862916A1 (en) * 1995-11-20 1998-09-09 Kiyoshi Kita External preparation containing vitamin d or vitamin k
EP0992242A1 (en) * 1997-06-10 2000-04-12 New Vision Co., Ltd. Vitamin d-containing preventives and/or remedies for conjunctival/corneal xerosis
US20050265998A1 (en) * 2003-12-10 2005-12-01 Greg Elson Neutralizing antibodies and methods of use thereof
WO2006121871A2 (en) * 2005-05-06 2006-11-16 The Scripps Research Institute Compositions and methods for modulating cells via cd14 and toll-like receptor 4 signaling pathway

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUDOUIN C: "[A new approach for better comprehension of diseases of the ocular surface]", JOURNAL FRANÇAIS D'OPHTALMOLOGIE MAR 2007, vol. 30, no. 3, March 2007 (2007-03-01), pages 239 - 246, XP002504005, ISSN: 1773-0597 *
CHANG J H ET AL: "Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease", BRITISH JOURNAL OF OPHTHALMOLOGY, LONDON, GB, vol. 90, no. 1, 1 January 2006 (2006-01-01), pages 103 - 108, XP009108391, ISSN: 0007-1161 *
MCPHERRAN R R ET AL: "Inflammation in corneal wound healing and dry eye", CLINICAL & REFRACTIVE OPTOMETRY, MEDIACONCEPT, MONTREAL, CA, vol. 16, no. 10, 1 January 2005 (2005-01-01), pages 294 - 299, XP009104008, ISSN: 1705-4850 *
STERN M E ET AL: "Inflammation in dry eye", OCULAR SURFACE, ETHIS COMMUNICATIONS, NEW YORK, NY, US, vol. 2, no. 2, 1 January 2004 (2004-01-01), pages 124 - 130, XP001538522, ISSN: 1542-0124 *

Also Published As

Publication number Publication date
WO2009002790A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2009007849A3 (en) Il-23 receptor antagonists and uses thereof
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2012139081A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2008116129A3 (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010065491A3 (en) Methods of treating inflammatory disorders
WO2006128032A3 (en) Compositions and methods for the prevention and treatment of conditions associated with inflammation
WO2008113834A3 (en) C5 antigens and uses thereof
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2006031922A3 (en) Thyroid hormone analogs for promoting angiogenesis
WO2009106975A3 (en) Activation of innate and adaptive immune responses by a ginseng extract
WO2012078633A8 (en) Methods of inhibiting metastasis from cancer
BRPI0922452A2 (en) compound, pharmaceutical composition, use in a compound, and method for preventing, treating or ameliorating dermal diseases or conditions, or acute or chronic skin injury disorders.
WO2009002790A3 (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2012112953A3 (en) Molecular switch for neuronal outgrowth
WO2005117972A3 (en) Preventing autoimmune disease by using an anti-cd20 antibody
WO2011143457A3 (en) Compositions and methods for treating or preventing atrial fibrillation
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
MX2009009471A (en) Spinner apparatus.
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2008021729A3 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
WO2008005686A3 (en) Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771419

Country of ref document: EP

Kind code of ref document: A2